In addition, given that KEAP1 mutations are common in NSCLC and are associated with poor prognosis and chemoresistance, the combination of artesunate and an NRF2 inhibitor may be a rational and effective combination therapy for future study. This evidence concerns the gene NFE2L2 and non-small cell lung carcinoma.